eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Review paper

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis

Lianghua Xiao
1
,
Xinwei Feng
2
,
Huahua Zhang
1
,
Lin Zhong
1
,
Xiaobing Song
2
,
Fangfang Wang
1

  1. Department of Nephrology, The Fifth People’s Hospital of Ganzhou, Ganzhou, China
  2. Department of Gastroenterology, The Fifth People’s Hospital of Ganzhou, Ganzhou, China
Adv Interv Cardiol
DOI: https://doi.org/10.5114/aic.2024.143558
Online publish date: 2024/09/27
Article file
- Efficacy of oral treprostinil.pdf  [0.08 MB]
Get citation
 
 
1. Chang KY, Duval S, Badesch DB, et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the Pulmonary Hypertension Association Registry. J Am Heart Assoc 2022; 11: e024969.
2. Xiao Y, Chen PP, Zhou RL, et al. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging Dis 2020; 11: 1623-39.
3. Sommer N, Ghofrani HA, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol 2021; 178: 6-30.
4. Lindegaard Pedersen M, Krüger M, Grimm D, et al. The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension. Basic Clin Pharmacol Toxicol 2020; 126: 32-42.
5. White RJ, Jerjes-Sanchez C, Meyer GMB, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension: a double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 2020; 201: 707-17.
6. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127: 624-33.
7. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142: 1383-90.
8. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144: 952-8.
9. Tran DL, Lau EMT, Celermajer DS, et al. Pathophysiology of exercise intolerance in pulmonary arterial hypertension. Respirology 2018; 23: 148-59.
10. Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One 2013; 8: e72013.
11. Desai SA, Channick RN. Exercise in patients with pulmonary arterial hypertension. J Cardiopulm Rehabil Prev 2008; 28: 12-6.
12. Moutchia J, Mcclelland RL, Al-Naamani N, et al. Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2023; 207: 1070-9.
13. Whittle BJ, Silverstein AM, Mottola DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol 2012; 84: 68-75.
14. Boucly A, Savale L, Jaïs X, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2021; 204: 842-54.
15. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007; 6: 45-52.
16. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008; 53 Suppl 1: S93-105.
17. Olschewski H, Rose F, Schermuly R, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004; 102: 139-53.
18. Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology 2014; 94: 148-56.
19. Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev 2016; 25: 18-30.
20. Gaine S, Mclaughlin V. Pulmonary arterial hypertension: tailoring treatment to risk in the current era. Eur Respir Rev 2017; 26: 170095.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.